Better lungs for better legs: novel bronchodilator effects in COPD

Peter Calverley

Limitation of exercise capacity plays a central role in the life of the patient with chronic obstructive pulmonary disease (COPD), both as a marker of well-being and as an indicator of a poor prognosis. Our ability to characterise this crucial aspect of disease has grown rapidly in the last decade and with this has our understanding of the many complex reasons for exercise impairment. It has long been recognised that the maximum ventilation during exercise is related to the initial FEV1 (forced expiratory volume in 1 s), with several formulae being developed to predict this. It was accepted that an inability to sustain a high level of ventilation would limit exercise performance in COPD, although exactly why this happened was uncertain. In the last decade there has been compelling evidence that changes in the operating lung volumes during exercise lead to mechanical limitation of inspiration and hence of tidal volume, which is associated with the sensation of breathlessness. Dynamic hyperinflation is a very consistent feature of COPD and can even occur early in the natural history of COPD, at least in symptomatic people. However, not all patients are limited exclusively by breathlessness on exertion, and data from the McMaster group in the 1990s pointed out that many patients were limited by a feeling of heaviness or fatigue in their legs, either along with breathlessness or dominating this sensation. As a result, attention...
began to turn to other factors, such as co-morbid cardiac disease and the possibility that skeletal muscle itself was not normal in COPD.7

One way of exploring the impact of lung disease on exercise performance is to study people before and after treatments designed to improve lung mechanics in some way. Bronchodilators improve operating lung volumes in subjects at rest and have been shown to increase exercise performance measured in a variety of ways in COPD. In a series of studies, Professor O’Donnell has shown that bronchodilators, both anticholinergics and β-agonists, improve exercise capacity and that this is best related to falls in the end-expiratory lung volume—that is, an increase in inspiratory capacity at rest and during exercise.8–10 Not all people benefit from this treatment, and we have previously described paradoxical responses where lung function appears to improve at rest but the response of the patient is abnormal and exercise tolerance worsens.11 How widespread such effects are has not been documented so far. Other groups found that bronchodilators were less effective when patients’ exercise performance was limited by the development of quadriceps muscle fatigue.12 These studies, and many others, have contributed to an active debate about the mechanisms limiting exercise performance in COPD which has recently been summarised.13

One important issue is the potential interaction between the effort made during respiration in patients with COPD and the cardiac output. Patients with COPD develop marked intrathoracic pressure swings which relate to some degree to the extent of abdominal muscle activation at rest and during exercise.14 There are now data suggesting that patients who show paradoxical movement of the lower ribcage are more likely to develop breathlessness on exercise, while those without this feature show a different pattern of chest wall hyperinflation and may be limited by leg fatigue.15 Thus the behaviour of the respiratory muscles and hence the intrathoracic pressures may be relevant to exercise performance. Direct measurements of cardiac output and peripheral muscle performance are inevitably difficult in these circumstances. The group from Brazil who report new findings in this issue of Thorax (see page 588)16 have previously established that there is a mismatch between oxygen uptake in the body in general and the rate at which oxygen in consumed within exercising skeletal muscle.17 Moreover, when subjects were breathing heliox, a gas mixture which reduces the mechanical work of breathing and also improves exercise performance in COPD,18 then the matching of oxygen delivery and oxygen uptake to the leg muscles of the patient with COPD was improved.19 Similar findings were seen when patients exercised while using proportional assist ventilation to decrease respiratory muscle work.20

Now Berton and colleagues have extended these observations to the clinically more relevant area of bronchodilator treatment. They studied 12 patients with severe COPD (FEV1 58.5% predicted) without resting arterial hypoxaemia in a series of constant work-rate cycle ergometer exercise tests conducted at 70–80% of a previously determined peak exercise performance. They did so before and after the patients had received the combination of ipratropium bromide and salbutamol by inhalation or an identical placebo. Their main outcomes were the speed with which whole body oxygen uptake changed during exercise and how this related to the change in oxygenation within the vastus lateralis muscle using near-infrared spectroscopy and in cardiac output measured by impedance cardiography. This comprehensive analysis allowed them to look at metabolic and cardiac output changes during exercise in COPD as well as the kinetics of peripheral muscle de-oxygenation. These complex studies produced some interesting results. As expected, the bronchodilators increased the exercise endurance time in constant work-rate exercise by almost 40% of the baseline performance, and the authors showed that there was less dynamic hyperinflation which they measured by the change in inspiratory capacity during exercise. The bronchodilators produced small but statistically significant improvements in both FEV1 and resting inspiratory capacity (130 and 390 ml, respectively), although only 7 of the 12 subjects would have met the conventional criteria for bronchodilator responsiveness. When the bronchodilators were administered there was an improvement in the speed with which the oxygen uptake and cardiac output reached the steady state, and there was a slowing of the desaturation which occurred in the exercising muscle measured as a change in the ratio of deoxygenated haemoglobin to myoglobin. Mismatch between delivery and oxygen consumption was improved by the bronchodilator drugs, and the greatest improvements in cardiac output kinetics were seen in the patients who showed the biggest reduction in dynamic hyperinflation postbronchodilator.

These elegant physiological studies have applied new methodologies which directly measure key variables that determine exercise performance in COPD. Inevitably the number of participants is small and the data apply to those with relatively severe disease. There is continuing controversy about the use of impedance cardiography to monitor cardiac output in patients with hyperinflated lungs, although the group from Sao Paulo have provided further evidence for its appropriateness in these studies. In practical terms, more direct and invasive methods of measuring cardiac output would pose formidable challenges even for determined investigators and patient volunteers, although data such as these may emerge in due course. Similarly, there has been some uncertainty about exactly what near-infrared spectroscopy is recording and how representative it is of overall muscle oxygenation. Despite these issues the data here represent a considerable technical achievement and point to a clinically relevant effect of bronchodilators on tissue oxygen delivery as well as lung function. How important these effects are in the overall limitation of exercise performance and why oxygen delivery is limited will be debated, although a direct effect of hyperinflation on cardiac function output seems increasingly likely. Whatever the mechanisms are, these data have implications for the way we view the symptomatic treatment in COPD. The effects of bronchodilators on cardiac function represent an additional potentially beneficial effect which could explain why in some circumstances, far from increasing cardiac mortality, use of long-acting inhaled bronchodilators is associated with a lower cardiac event rate.21 It is also relevant to ask our patients why they are limited when they exercise, and recognise that developing tiredness in the legs is not just a sign of being unfit but may be a direct effect of lung disease on their muscle function. We should no longer be surprised when they tell us their legs are less tired after taking their inhalers because, as usual, the patient has got it right before the doctor can explain why this happens.

Competing interests None.

Provenance and peer review Commissioned; not externally peer reviewed.


REFERENCES

Diagnosing cystic fibrosis in patients with non-diagnostic results: the case for intestinal current measurements

J P Clancy

Cystic fibrosis (CF) is a well-described genetic disease with characteristic defects in ion transport in disease-affected tissues. CF results from dysfunction of the cystic fibrosis transmembrane conductance regulator protein (CFTR) which is an ATP binding cassette protein that, in addition to chloride channel function, regulates other ion transport pathways such as sodium channels, other chloride channels and bicarbonate transport.1 Diagnosing CF is generally straightforward in patients with classic disease and builds upon these basic ion transport features, with well-defined clinical manifestations combined with elevated sweat chloride values, nasal ion transport abnormalities and/or common CFTR mutations.2 Newborn screening algorithms have added elevated serum immunoreactive trypsinogen levels to the diagnostic pathway (typically prior to symptoms), and together allow healthcare providers to confidently provide diagnostic and prognostic information to the majority of families and patients with CF.3

Unfortunately, there is a spectrum of disorders that have been linked to CFTR dysfunction which may not fulfil the diagnostic criteria for CF. In general, these milder manifestations of CFTR dysfunction can present in numerous ways such as recurrent upper and lower airway respiratory symptoms, pancreatic disease, male infertility, liver disease and vague gastrointestinal symptoms.3–5 Standard CF diagnostic testing may provide information that is conflicting or sits squarely in the ‘grey zone’, with intermediate sweat chloride values (above the normal range but below the CF diagnostic cutoff), nasal potential difference measurements with both CF and non-CF features, inconclusive genetic testing and additional (less specific) clinical measurements that may support a CF diagnosis but are not able to define the disease (such as abnormal stool elastase measurements, intermittent detection of CF respiratory pathogens or evidence of obstructive airway disease but without clearcut bronchiectasis). These patients are difficult to counsel and care for, as the absence of a clear diagnosis can undermine adherence to treatments and long-term prognostic information is insufficient. Carrying an erroneous CF diagnosis can have detrimental emotional, financial and quality of life implications for the patient and family, while failing to secure a diagnosis of CF puts patients at risk of permanent organ damage and premature death. Thus, for these diagnostic dilemmas, there remains a need to isolate and define CFTR function (or dysfunction) in patient-derived tissue. All available clinical tests of CFTR function are performed in vivo, which limits the available reagents and assays to those that can be performed safely in patients. In this issue of Thorax, Derichs and colleagues6 describe the use of intestinal current measurements (ICM) to diagnose CF, examining this assay in subjects with classic pancreatic-insufficient CF, pancreatic-sufficient CF, non-CF participants and

Better lungs for better legs: novel bronchodilator effects in COPD

Peter Calverley

Thorax 2010 65: 573-575
doi: 10.1136/thx.2010.135129

Updated information and services can be found at:
http://thorax.bmj.com/content/65/7/573

These include:

References

This article cites 21 articles, 13 of which you can access for free at:
http://thorax.bmj.com/content/65/7/573#BIBL

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/